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Abstract—Stereochemically constrained amino acid residues that strongly favour specific backbone conformations may be used to
nucleate and stabilize specific secondary structures in designed peptides. An overview of the use of aa-dialkyl amino acids in sta-
bilizing helical structures in synthetic peptides is presented, with an emphasis on work carried out in the authors laboratory. a-Ami-
noisobutyric acid (Aib) and related achiral homologs facilitate stable helix formation in oligopeptides as exemplified by a large
number of crystal structure determinations in the solid state. The ability to design conformationally rigid helical modules has been
exploited in attempts to design structurally well characterized helix-linker–helix, using potential nonhelical linking segments. b-
Hairpin design has been approached by exploiting the tendency of ‘prime turns’ to nucleate hairpin formation. The use of nucleating
DPro-Gly segments has resulted in the generation of several well characterized b-hairpin structures, including the crystallographic
observation of b-hairpin in a synthetic apolar octapeptide. Extensions of this approach to three stranded b-sheets and larger
structures containing multiple DPro-Gly segments appear readily possible.
Introduction
The rich diversity of 3-dimensional folds in protein
structures is generated using very few elements of sec-
ondary structure, like helices, strands, and turns that are
connected by irregular loops and packed together in a
compact fashion.1,2 A precise relationship between pro-
tein sequence and 3-dimensional structure is still to be
firmly established. However, the enormous activity in
the area of protein structure and folding has provided
many powerful insights into the determinants of sec-
ondary and tertiary folding in polypeptide sequences.3,4
The construction of designed sequences with predictable
folding patterns is a critical test of our understanding of
the principles that relate amino acid sequence to the
polypeptide 3-dimensional structure. De novo design
approaches have been intensively investigated over the
past decade leading to notable successes in the area of
construction of helical bundles5–9 and metal binding
motifs.10–13 The design of b-sheet proteins from first
principles has been less successful partly because of
practical diculties associated with the limited solubi-
lities of designed polypeptide sheets.14–18 Most approa-
ches to de novo design address the problem of
constructing a water soluble structure as a protein
mimic. The heart of these strategies involves choice of
sequences that favour a specific secondary structure (for
example, helix or strand) followed by a reliance on the
dominant role of hydrophobic interactions in generating
compact super-secondary structural motifs. The success
of these strategies is then based on a patterning of
hydrophobic and polar residues along the sequence, in
order to generate amphipathic secondary structure ele-
ments.19–21 In some cases the use of appropriately posi-
tioned liganding groups permits metal ion directed
assembly.22–25 A novel approach to assembly of sec-
ondary structures is based on covalent attachment of
multiple polypeptide chains to a suitable template lead-
ing to the concept of template assisted synthetic protein
(TASP).26–28 In most approaches, the choice of sequen-
ces is based on secondary structure propensities derived
from analysis of protein crystal structures.29,30
A completely dierent approach to synthetic protein
design involves stabilization of specific secondary struc-
tures by the use of stereochemically constrained non-
protein amino acids31 or by the use of synthetic
templates, which permit nucleation of helices,32,33 or
sheets.34–38 In these cases, the designed peptides are
often soluble in organic solvents, with folding being
primarily driven by local stereochemical influences. This
overview examines the use of stereochemically con-
strained amino acid residues in directing polypeptide
chain folding.
Polypeptide chain conformations are determined by the
two degrees of torsional freedom about N–Ca (f) and
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Ca–C0O (c) bonds (Fig. 1). The torsional angle about
the peptide bond C0–N is restricted to either 180 (trans)
or 0 (cis), with the former being overwhelmingly pre-
dominant in peptide and protein structures. The diverse
backbone conformations assumed by polypeptide
chains in proteins is then a consequence of the nature of
the f, c values at individual residues. The seminal work
of Ramachandran and co-workers established that ste-
reochemically allowed backbone conformations were
largely determined by simple van der Waals criteria,
which precluded nonbonded atoms from coming closer
than specified ‘contact limits’.39–41 Figure 2 shows the
Ramachandran (contact) map for the Gly residue,
which contains two hydrogen atoms bonded to the tet-
rahedral Ca atom. Almost 60% of conformational space
is stereochemically allowed for the Gly residue. Figure
2(b) shows the Ramachandran map for the l-Ala resi-
due demonstrating that replacement of hydrogen at the
Ca atom by a methyl group results in a dramatic
shrinking of the allowed regions of f, c space. Most
noteworthy, is the fact that for the l-Ala residue
allowed values of f are almost invariably negative, with
only a small region of positive values being allowed in
the right handed top quadrant of the f, c map. Figure 3
illustrates the superposition of Ramachandran maps for
l-Ala and d-Ala residues, which are precisely related
by inversion about the origin. It is immediately appar-
ent that only a very small region of f, c space is allowed
for both l-Ala and d-Ala residues. Clearly, subsititu-
tion of the a-hydrogen in l-Ala by a methyl group
should lead to an achiral residue in which the Rama-
chandran allowed regions are limited to those shown in
Figure 4. a,a-Dialkyl amino acid residues should there-
fore be extremely conformationally restricted, with
allowed conformations lying largely in the region
f60, c30. This line of reasoning first led Rama-
chandran and Chandrasekaran42 in 1970 to suggest
that the a-aminoisobutyryl residue (Aib, a-methylala-
nyl, a,a-dimethylglycyl) would be a conformationally
restricted residue favouring helical conformations.
Concurrently, Marshall and Bosshard,43 using con-
formational energy calculations suggested that Aib
residues should favour helical f, c values. Shortly
thereafter Burgess and Leach on the basis of PCILO
calculations suggested that Aib is an obligatory helical
residue.44 The occurrence of Aib residues in diverse
fungal polypeptides and the remarkable membrane
channel forming properties exhibited by alamethicin,
and related natural peptides, stimulated considerable
synthetic and conformational work on Aib containing
peptides.45,46 The first crystal structures of acyclic Aib
containing peptides provided convincing evidence for
the tendency of Aib residues to adopt helical f, c
values.47–49 In the last two decades, a very large number
of Aib containing peptide crystal structures have been
determined, which demonstrate an overwhelming ten-
dency of these residues to promote helical conforma-
tions50–53 (Fig. 5). A cursory review of the Cambridge
Data Bank reveals that of the 5127 peptide entries, 132
correspond to crystal structures of Aib peptides. While
the overwhelming majority of peptide crystal structures
are of short sequences less than 6 residues in length,
there are many examples of crystalline Aib containing
oligopeptides in the size range 7–16 residues. Interest-
ingly, while small proteins 5 50 residues in length crys-
tallize relatively easily, acyclic oligopeptides in the range
of 6–40 residues are much more dicult to crystallize.
This has led to a ‘grey area’ in the crystallographic
characterization of polypeptide structures. There are a
relatively large number of accurate structure determi-
nations of short peptides and a growing body of struc-
tural information on large proteins; but paradoxically
structural information on intermediate size peptides is
meagre. Many important biologically active peptides
fall into this class. The incorporation of stereo-
chemically constrained aminoacids facilitates crystal-
lization of longer sequences. The abundance of
crystallographic data on relatively long Aib peptides is
testimony to their ready crystallizability; a feature that
is undoubtedly linked to their limited conformational
heterogeneity in solution coupled to the decided advan-
tages in packing cylindrical helical molecules into crys-
tals.54 The ability of Aib residues to nucleate and
stabilize helical conformations in oligopeptides is illu-
strated by the observation of helical structures in crystals
of heptapeptides containing a single Aib residue.55,56
Figure 1. Ball and stick representation of a dipeptide unit. The dihe-
dral angles f,c and o are marked.
Interestingly, the conformational constraints imposed
by Aib force even proline residues into occupying posi-
tions within short helical segments as demonstrated in
the crystal structure of Boc-(Val)2-Aib-Pro-(Val)3-OMe.
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Figure 6(a) illustrates the crystal state conformation of
two 16-residue peptides Boc-(Val-Ala-Leu-Aib)4-OMe
and the natural product [Leu]1-zervamicin (Fig. 6(b)),
While the former provides an example of approximately
four turns of a straight helix,58 the latter adopts a
curved or bent structure due to the presence of as many
as three Pro/Hyp residues in the C-terminus segment.59
There has been considerable discussion in the literature
on the nature of the helical conformations adopted by
Aib rich sequences.51,53,60,61 Both 310 and a-helical
conformations have been characterized depending upon
peptide length, sequence and Aib content. Several
structures of heteromeric sequences containing Aib have
revealed mixed 310/a-helical structures,51,62,63 with the
310 segment often occuring at the N-terminus. The 310
helix is a structure stabilized by successive 4!1
CO. . .NH hydrogen bonds, with idealized f, c values of
ÿ60, ÿ30 for the right handed screw sense. The a-helix
is stabilized by successive 5!1 hydrogen bonds with
idealized f, c values ÿ55, ÿ45 for a right handed
structure. The distinctions between these two helical
types are subtle and involve very small changes in f, c
values. Conformational interconversion between 310
and a-helices can be easily achieved and have been the
subject of several theoretical investigations.64–68 Dis-
tinctions between these two structures in solution are
not readily achieved69 although circular dichroism,70,71
NMR,72 ESR73–75 have all been suggested as potential
Figure 4. Potential energy map for Ac-Aib-NHMe computed theore-
tically. The counters are drawn at 1Kcal/mol intervals with respect to
the innermost contour enclosing the minimum. The ideal 310(r) and a-
helical (o) conformations are marked.
Figure 2. The Ramachandran map for the N-acetyl-N0 methylamide of (a) glycine (b) l-alanine. The dark shaded area corresponds to the fully
allowed region and the light shaded zone encloses partially allowed regions.
Figure 3. Superposition of the Ramachandran maps for the N-acetyl-
N0-methylamides of l-alanine and d-alanine.
diagnostic techniques. For purposes of conformational
design of protein mimics, a precise distinction between
310 and a-helical structures is largely unnecessary.
The widely documented ability of Aib to stabilize helical
conformations in peptides has been used to construct
stereochemically well defined helical modules that can
then be assembled into supersecondary structures like
helix–helix motifs using appropriate linking segments.
This approach constitutes a modular strategy for the
construction of synthetic protein mimics and has been
termed as a ‘Meccano (Lego) Set’ approach.31,76
Higher homologs of Aib
Figure 7 illustrates the structures of symmetrical a,a
dialkylglycines, which are higher homologs of Aib. Two
classes of amino acid residues can be considered, viz,
residues with linear alkyl side chains (Deg=diethylgly-
cine; Dpg=di-n-propylglycine; Dbg=di-n-butylglycine)
and residues with cycloalkyl side chains (1-amino-
cycloalkane-1-carboxylic acids, Acnc, where n is the
number of carbon atoms in the cycloalkane ring). Con-
formational energy calculations on Ac-Ac6c-NHMe
reveal that the NH axial conformer is about 1.6 kcal/
mole more stable than the NH equatorial form. Con-
formational energy maps have been computed for both
the axial and the equatorial forms of the Ac6c residue
(Fig. 8). Pronounced energy minima are located in the
right and left handed 310/a-helical regions of f, c
space (f60, c30).77 Crystal structure determi-
nations of short Ac6c containing peptides quickly con-
firmed this expectation.77–79 Helical conformations were
also demonstrated in structure determinations involving
Ac5c,
80,81 and Ac7c
82 peptides. The Acnc residues
appear predominantly to be limited to helical con-
formations. The crystal structure of the octapeptide
Boc-Leu-Ac8c-Ala-Leu-Ac8c-Ala-Leu-Ac8c-OMe pro-
vides an example of a relatively long helical segment
containing pendent cyclooctane rings on one helical
face (Fig. 9) (Datta, S.; Shamala, N.; Vijayalakshmi, S.;
Rao, R. B.; Balaram, P. unpublished). In contrast to the
Acnc residues, theoretical calculations suggest that for
the linear dialkyl glycines (Dxg) fully extended con-
formation (f  c 180, C5) are energetically slightly
more favourable than folded helical conformations.83–85
Indeed, crystal structures of short homooligopeptides
ranging in length up to 5 residues yielded fully extended
C5 conformations in crystals.
86,87 However, many recent
crystal structure determinations of Dpg and Dbg con-
taining peptides have yielded helical conformations. In
short heteromeric sequences, both folded and extended
Dpg conformations have been characterized. For exam-
ple, in the chemotactic tripeptide analogue For-Met-
Dpg-Phe-OMe the Dpg residue adopts an extended
conformation. (f 173 c 179).88 In crystals of the
tripeptide Boc-Leu-Dpg-Val-OMe (Fig. 10) two inde-
pendent molecules are observed in the crystallographic
asymmetric unit with one adopting helical f, c values
(f=62.8, c=39.6) and the other taking up an exten-
ded conformation (f 176, c ÿ180).89 Interestingly
even in the homotripeptide Tfa-(Dpg)3-DBH (DBH=
N,N(-dibenzyl-hydrazide), all the three Dpg residues
adopt helical f, c values.90 Recent studies from our
laboratory have attempted to probe the eect of local
sequence variations on Dpg residue conformation.91–95
Even in the context of flanking Gly residues, which
have a low helical propensity, helical conformations
have been observed in the 14-residue peptides Boc-Val-
Val-Ala-Leu-Gly-Dpg-Gly-Val-Ala-Leu-Aib-Val-Ala-Leu-
Ome.96 It is noteworthy that in the tripeptide Boc-Gly-
Dpg-Gly-OH, the Dpg residue adopts an extended
conformation, in contrast to the conformation of this
segment in the longer peptide.96
The body of accumulated evidence suggests that helical
conformations are likely to be favoured at the Dpg
residues in long heteromeric sequences. Fully extended
and helical conformations at Dxg residues appear to
be characterized by distinctly dierent bond angles
(N–Ca–C, t) at the tetrahedral Ca atom. Values between
101 and 105 are noted for fully extended conforma-
tions, while values between 105 and 113 are seen for
helical conformations. The dependence of conforma-
tional energies on the bond angle t has previously been
established by theoretical calculations.85 Two crystal
structures of a heptapeptide sequence containing a sin-
gle centrally located Dpg residue Boc/Ac-Val-Ala-Leu-
Dpg-Val-Ala-Leu-OMe reveal helical conformations.
Comparison of the helix stabilities of helical peptide
Boc-Val-Ala-Leu-Xxx-Val-Ala-Leu-OMe (Xxx=Ac8c,
Ac7c, Aib, Deg, Dpg) suggest that the Dxg containing
helices are more prone to solvent invasion and unravel-
ling in strongly solvating media (Vijayalakshmi, S.;
Rao, R. B.; Karle, I. L.; Balaram, P. unpublished). The
higher homologs of Aib with both linear and cycloalkyl
side chains may be used to impose severe conforma-
tional restraints on the peptide backbone. The tendency
of these residues to adopt ‘local helical’ conformations
may be exploited in the design of b-turns in short pep-
tides. The ability to vary the bulk of the hydrophobic
side chains at the i+1/i+2 positions of b-turns has
Figure 5. Crystallographically observed f,c values of Aib residues
from 178 independent crystal structures of Aib containing peptides. A
total of 534 Aib residues are marked. In the case of achiral peptides
crystallizing in a centrosymmetric space group, the sign of the dihedral
angles has been chosen arbitrarily.
been used to probe structure activity relationships for
chemotactic peptide analogues binding to the formyl
peptide receptor on neutrophils.97 In summary Aib and
related diakylglycines, are powerful stabilizers of helical
conformations permitting the design of well character-
ized helical molecules.
Design of helix–helix motifs
Prefabricated helical modules may be assembled into
helix-linker–helix motifs using nonhelical linking seg-
ments. In proteins, helix–helix motifs containing short
linker segments (1–5 residues) have been analyzed and
specific families of linkers identified on the basis of their
f, c values.98,99 Helix orientation is a function of linker
conformation. Most attempts at helix–helix motif con-
struction utilize conformationally flexible linkers, with
the expectation that appropriate helix orientation can
be achieved by suitable interhelix interactions. Most
commonly, the design of helical bundles has been
approached by utilizing amphiphilic helical sequences so
that nonpolar helix faces are brought into close proxi-
mity under the influence of hydrophobic driving for-
ces.5–9 Helix–helix motifs and helical hairpins have been
approached by linking peptide segments with high helix
propensities by short polar loops containing amino
acids with limited tendencies to adopt helical con-
formation. Implicit in these strategies is the formation
Figure 6. (a) Crystal structure of Boc-(Val-Ala-Leu-Aib)4-OMe showing a ‘straight helix’. The C
a atoms are numbered. (b) Crystal structure of
[Leu]1-Zervamicin. The helical structure is amphiphilic with all polar moieties on the convex side of the bent helix. Bending is a consequence of the
alternating (Aib-Pr0/Hrp)3 sequence at the C-terminus.
of a ‘hydrophobic core’ formed by close interhelix con-
tacts involving nonpolar side chains.100–102 In the
absence of favourable solvent forces it is necessary that
conformational control be exercised over the linking
segments or that specific attractive interactions be
designed between the helix segments. Several explora-
tory investigations in this laboratory have been direc-
ted towards the design of helix–helix motifs that are
soluble in relatively inert organic solvents. The use of
short polymethylene chains has been investigated using
e-aminocaproic acid (Acp) linkers. Crystallographic
determinations of the structures of two 15-residue pep-
tides Boc-Val-Ala-Leu-Aib-Val-Ala-Leu-Acp-Val-Ala-
Leu-Aib-Val-Ala-Leu-OMe and Boc -Val-Ala-Leu-Aib-
Val-Ala-Leu-Acp-DVal-DAla-DLeu-Aib-DVal-DAla-DLeu-
OMe have revealed an extended arrangement of the two
helical segments with an interhelical angle close to
180.103,104 Limited evidence based on interaction with
hydrophobic reverse phase C18 columns suggests that
these peptides adopt more compact structures in solu-
tion.76 A detailed study of an analogue peptide Boc-
Met-Ala-Leu-Aib-Val-Ala-Acp-Val-Ala-Leu-Aib-Val-
Ala-Phe-OMe has provided evidence for a folded U-
shaped arrangement of the two helices in an apolar
solvent like chloroform.105 The use of d-residues as
potential helix breakers has been investigated in
the sequences Boc-Val-Ala-Leu-Aib-Val-Ala-Leu-DPhe-
Pro-Val-Ala-Leu-Aib-Val-Ala-Leu-OMe and Boc-Val-
Ala-Leu-Aib-Val-Ala-Leu-LPhe-Pro-Val-Ala-Leu-Aib-
Val-Ala-Leu-OMe. Despite the presence of a centrally
located DPhe-Pro segment, a continuous helix has
been inferred in the 16-residue peptide from NMR
studies.106 An extension to three residue linkers has
been attempted in the sequence Boc-Leu-Aib-Val-Ala-
Leu-Aib-Val-DVal-LPhe-DPro-Val-Ala-Leu-Aib-Val-Ala-
Leu-OMe. In this sequence, the two helical segments
encompassing residues 1–7 and 11–17 have been con-
formationally characterized in crystals of the corre-
sponding Boc-protected heptapeptide methyl esters. The
incorporation of DVal and DPro into the three residue
linking segment necessarily impedes continuous helix
formation. Specifically, DPro is restricted to f
+6020, which is incompatible with its insertion into
a right handed helix (f ÿ60 c ÿ30). Further, the
absence of an NH group in DPro limits the hydrogen
network preventing incorporation of DVal into a con-
tinuous helix. A central LPhe residue was introduced as
an NMR spectroscopic marker and also to facilitate the
Figure 7. Structures of symmetrical a,a-dialklglycines.
Figure 8. Conformational energy maps for Ac-Ac6c-NHMe (a) -NH-axial, (b) -NH-Equatorial.
formation of a type II b-turn involving LPhe-DPro resi-
dues, which should then orient the two helical segments
in an approximately antiparallel fashion. A common
helix terminating motif in proteins involves local rever-
sal of helix sense resulting in the formation of a 6!1
hydrogen bond at the C-terminus, termed as the Schell-
mann motif.107–110 In the case of short synthetic pep-
tides the terminating residue has invariably been the
achiral residue Aib,111,112 whereas in proteins Gly is
most frequently found.113 In the case of the DVal-
LPhe-DPro linker, inversion of configuration at residue
8 (DVal) should facilitate Schellmann motif formation
and consequent helix termination with DVal adopting a
left handed helical (aL) conformation. The residue 9
(LPhe) can be assigned either a or b conformations.The
residue 10 (DPro) is restricted to values of +60, ÿ120
(bL) or +60, +30 (aL). Figure 11 illustrates the rela-
tive orientation of two helical segments for four dis-
tinct stereochemical alternatives for the linking
tripeptide segments. Clearly, two orientations corre-
spond to relatively compact close packed arrangement
of the two helices. One of the two compact arrange-
ments involves type II b turn formation at the LPhe-
DPro segment, which would bury the Val (11) NH in an
intramolecular 4!1 hydrogen bond. Interestingly,
NMR studies on the 17 residue peptide in CDCl3 sug-
gests that Val (11) NH is shielded from the solvent as
evidenced by its inaccessibility to perturbing reagents
like DMSO and the free radical 2,2,6,6-tetra-
methylpiperidinyl-1-oxyl (TEMPO). Unfortunately, this
peptide has proved recalcitrant to crystallisation (Kaul,
R.; Balaram, P. unpublished).
-Hairpin design
b-Hairpins may be considered as the simplest element of
supersecondary structure amenable to synthetic design.
In b-hairpins two extended strands are brought together
to form an antiparallel b-sheet structure via a nucleating
b-turn (Fig. 12). Analysis of b-hairpins in protein
crystal structures have revealed that a very sizable frac-
tion of these structures incorporate type I0 or type II0 b-
turns as the nucleating segment.114–117 These two types
of turns are conformationally defined as follows: type I0
(fI+1=60, ci+1=30; fi+2=90, cI+2=0), type II0
(fi+1=60, ci+1=ÿ120; fi+2=ÿ90, ci+2=0),
where i+1 and i+2 are the turn forming residues. The
occurrence of ‘prime turns’ with one or both residues
adopting positive f values facilitates registry of the two
antiparallel strands. Designed synthetic b-hairpins must
therefore accomodate two simple stereochemical fea-
tures; (i) a turn segment that is constrained to type II0 or
I0 b-turn conformations and (ii) strand segments that
are rich in residues that favour relatively extended con-
formations (f  ÿ120, c +120). DPro is the residue
of choice for nucleating type I0/II0 conformations since
the constraints of pyrrolidine ring formation restricts
fDPro to +6020. These simple considerations have
led to the construction of the octapeptide Boc-Leu-Val-
Val-DPro-Gly-Leu-Val-Val-OMe for which nuclear
Overhauser eects and hydrogen bonding studies clearly
established a b-hairpin conformation in solution,118
Figure 10. Structures of the two crystallographically independent molecules in crystals of Boc-Leu-Dpg-Val-OMe showing (a) extended Dpg con-
formation. (b) folded Dpg conformation.
Figure 9. Stereoview of the octapeptide Boc-Leu-Ac8c-Ala-Leu-Ac8c-
Ala-Leu-Ac8c-Ala-Leu-Ac8c-OMe in crystals showing three pendent
cyclooctane rings. The Ca (CA) atoms are labelled.
Figure 11. Four distinct stereochemical alternatives for a helix-linker–helix peptide, containing two 7-residue helical segments linked by a 3-residue
loop (residues 8–10). The backbone conformations at the 3-residues in the linking segments are indicated. Only the N–Ca–C0 backbone is shown.
which was later confirmed by X-ray diraction in crys-
tals119 (Fig. 13). A detailed comparison by NMR spec-
troscopy of the octapeptide Boc-Leu-Val-Val-DPro-Gly-
Leu-Val-Val-OMe and Boc-Leu-Val-Val-LPro-Gly-Leu-
Val-Val-OMe reveals that the hairpin formation was a
specific feature of the DPro containing sequences.120 The
use of DPro to facilitate b-hairpin formation is also
exemplified in a 23-residue peptide Ac-Tyr-Thr-Val-
DPro-Ser-Fen-Thr-Phe-Ser-Arg-Ser-Asp-Leu-Ala-Lys-
Leu-Leu-Leu-Arg-Leu-His-Ala-Gly-NH2 having a bba
architecture of a putative Zn finger. Here the key step in
the design was the replacement of LPro4-DSer5 by
DPro4-Ser5, that is, conversion of a type II b-turn to a
type II0 b-turn, which had the dramatic eect of indu-
cing b-hairpin conformation in the N-terminal octapep-
tide segment, thereby stabilizing the tertiary structure of
the motif.121,122 Folding of small tetrapeptide segments
into b-hairpin loops as a result of introduction of a
DPro-X segment instead of LPro-X has also been
described in the study of model peptides Ac-Val-LPro-
Gly-Leu-NMe2 and Ac-Val-
DPro-Gly-Leu-NMe2.
123
Similar observations have been made from the studies
on peptide fragments derived from the N-terminal seg-
ment of ubiquitin.124
Recent studies in this laboratory have extended this
approach to the design of synthetic 3-stranded b-sheet
structures. A 14-residue peptide Boc-Leu-Phe-Val-DPro-
Gly-Leu-Val-Leu-Ala-DPro-Gly-Phe-Val-Leu-OMe,
which contains two centrally located DPro-Gly seg-
ments has been shown to form the three-stranded
structure illustrated in Figure 14 in CDCl3 solution.
125
Clear evidence for the postulated conformation is
obtained from backbone–backbone and side chain–side
chain interstrand nuclear Overhauser eects, along with
complete delineation of intramolecularly hydrogen
bonded NH groups. The use of DPro-Gly segments in
water soluble peptides has also been shown to facilitate
b-hairpin formation. For example, Serrano et al. (1996)
reported a water soluble b-hairpin Arg-Gly-Ile-Thr-Val-
Asn-Gly-Lys-Thr-Tyr-Gly-Arg in which NMR studies
are consistent with a population of 35% of the
Figure 12. Definition of a two-residue loop b-harpin. Strand length of
4-residues. The strand and loop positions are designed as BX and L-
X, respectively.
Figure 13. Crystal structure of the octapeptide Boc-Leu-Val-Val-DPro-
Gly-Leu-Val-Val-OMe showing an almost ideal b-hairpin structure
with a type II0 b-bend at DPro4-Gly5 for both molecules in the crys-
tallographic assymmetric unit.
desired conformation.126 Studies in this laboratory on
the analogue peptide Arg-Gly-Ile-Thr-Val-DPro-Gly-
Lys-Thr-Tyr-Gly-Arg reveal that the replacement of
Asn in the turn segment by DPro results in a dramatic
increase in the population of b-hairpin structures
(unpublished). The superiority of the DPro-Gly segment
as a strong b-hairpin inducer over the Xxx-Gly
(Xxx=Asn, LPro) segment has been recently shown in a
12-residue peptide Arg-Tyr-Val-Glu-Val-Xxx-Gly-Orn-
Lys-Ile-Leu-Gln.127 Special mention must be made of
the construction of a three-stranded water soluble
b-sheet structure in a 20-residue sequence containing two
centrally located Asn-Gly turns.128 The nucleation of
‘prime b-turns’ by incorporation of DPro residues
appears to be a powerful means of inducing b-hairpin
conformations. In organic solvents where interstrand
hydrogen bonding is a major determinant, both isolated
b-hairpin and multiple hairpins resulting in b-sheets can
be characterized. In aqueous solutions, solvent invasion
limits the stabilization aorded by interstrand hydrogen
bonding. Thus, although the b-turn segment may be
readily nucleated, extension to stable hairpins and
sheets requires building in appropriate sidechain inter-
actions. This successful design of organic solvent soluble
three stranded b-sheet is of relevance in attempts to
mimic b-barrel structures found in bacterial porins.129
Figure 14. Superposition of a family of ten structures of the 14 residue peptide sequence Boc-Leu-Phe-Val-DPro-Gly-Leu-Val-Leu-Ala-DPro-Gly-
Phe-Val-Leu-OMe obtained using restrained molecular dynamics with NOE-derived interproton distance constraints.
Applications of conformationally constrained peptide
modules
The ability to construct relatively rigid elements of sec-
ondary structure, particularly helices, have found varied
applications in dierent areas of chemistry. Kishi and
co-workers have attempted to use chiral helices gener-
ated using Aib rich sequences along with l-aminoacids
as a template for attaching farnesate in order to achieve
enantioselective terminal epoxidation; in an attempt to
mimic the mechanistic feature of cholesterol biosynth-
esis.130 Rigid helices formed in Aib-rich peptides have
proved particularly useful in probing electron transfer
mechanisms between donor and acceptor groups that
are brought into spatial proximity on the same helix
face.131–133 Hydrophobic helices formed by alternating
(Ala-Aib)n sequences have been used to generate cation
binding peptides by means of covalently attached crown
ethers. These systems have provided useful information
on aggregation and ion-channel formation in lipid
bilayer membranes. The ability to easily attach relevant
functionalities at the termini of peptides have been
exploited in generating biotinylated hydrophobic,
helical, Aib containing peptides that have been used
to study streptavidin binding at air–water inter-
phases.134,135 Cylindrical helical structures readily gen-
erated in Aib rich sequences are likely to find many
novel applications in material science. Relevant recent
reports include the synthesis of monodisperse liquid
crystalline peptides based on Aib containing helices136
and the formation of self assembling chiral monolayers
of helical peptides bound to gold surfaces, in which
immobilization is achieved by side chain thioether
interaction.137
Conclusions
This article illustrates the use of conformationally con-
strained amino acid residues like aa-dialkylglycines and
DPro in generating modules of defined secondary struc-
tures. Conformationally constrained residues may be
used to advantage in the design of specific folded struc-
tures in peptides. The diversity of polypeptide con-
formations arises due to the sampling of dierent
allowed Ramachandran conformations at individual
residues in a polymeric chain. In regular structures the
backbone torsional angles lie within a limited region of
f, c space for successive residues. The incorporation of
stereochemically constrained residues limits the f, c
values at a specific position in the sequence, thereby
acting as a nucleus for formation of regular structures.
Nonstandard amino acids with suitable stereochemical
properties may therefore be valuable as conformational
directors of polypeptide chain folding, permitting the de
novo design of novel peptide structures.
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